SEC Form 4 · accession 0001209191-18-029373
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Susan M Kanaya
Officer — EVP, CFO and Sec.
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 7:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2018 | M | 65,328 | $6.00 | A | 103,463 | D | |
| Common StockF2,F3 | May 8, 2018 | S | 65,328 | $11.5253 | D | 38,135 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $6.00 | May 8, 2018 | M | 65,328 | D | Sep 10, 2008 | Sep 10, 2018 | Common Stock | 65,328 | 8,306 | D |
Explanation of responses
- F1Shares sold are associated with stock options that will expire in September 2018.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $11.50 to $11.60 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F4As of May 8, 2018, and prior to this transaction, the exercised options were fully vested.
- F5Not applicable.